Envudeucitinibum

Overview

Envudeucitinibum (Envudeucitinib) is a highly selective, allosteric and orally active TYK2 inhibitor binding to the JH2 domain of TYK2 . Envudeucitinibum has no off-target effects on other kinases (JAK1-3). Envudeucitinibum reduces signaling and production of proinflammatory cytokines including IL-12 , IL-23 , IL-17 , and type I interferons (IFNs) . Envudeucitinibum can be used for the research of plaque psoriasis, systemic lupus erythematosus (SLE), and other immune-mediated diseases .

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Skin Inflammation | Products > Disease Areas > Systemic Lupus Erythematosus | Products > Disease Areas > Psoriasis | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Others | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > IFNAR | Products > Signaling Pathways > Isotope-Labeled Compounds | Products > Signaling Pathways > JAK | Products > Signaling Pathways > Interleukin Related

Product Information

• Catalog No.: HY-153701S
• CAS No.: 2417135-66-9
• Molecular Formula: C22H18D6N6O3
• Molecular Weight: 426.50
• Purity: 99.56%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (5.86 mM); Clear solution
• Availability: In-stock

Source

Original product source